Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Cowen & Co. Downgrades Macrogenics to Market Perform

Cowen & Co. analyst Boris Peaker downgrades Macrogenics (NASDAQ:MGNX) from Outperform to Market Perform.
byBenzinga Newsdesk
November 22, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Cowen & Co. analyst Boris Peaker downgrades Macrogenics (NASDAQ:MGNX) from Outperform to Market Perform.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Biomea Fusion Presents Achievement Of Minimal Residual Disease Negativity In First Complete Responder From Ongoing Phase I Study Of BMF-219 In Patients With Relapsed Or Refractory Acute Myeloid Leukemia At The 2023 ASH Annual Meeting

By Benzinga Newsdesk
December 11, 10:27 AM
BMF-219 demonstrated early signs of clinical activity and ability to achieve durable and sustained complete responses (CRs) with minimal residual disease negativity (MRD-neg) in acute myeloid leukemia (AML)

BMEA

Read More

What’s Going On With Nvidia’s Stock?

By Erica Kollmann
May 6, 1:59 PM
Analysts remain bullish on Nvidia, with a consensus price target of $949.36 a share and a rating of "Buy" for the stock, with the most recent ratings citing a potential upside of 31.5% from the current price. Nvidia is set to report its first-quarter financial results on May 22 after the market close. According to estimates from Benzinga Pro, analysts expect the company to report earnings of $5.55 per share and quarterly revenue of $22.103 billion.

NVDA